ArticleFrontiers in medicine2026
Cross-disease immune cells atlas reveals the similarities and differences of cell characteristics and interactions in rheumatic diseases.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rheumatic diseases are a group of immune-mediated inflammatory disorders, in which abnormal activation of immune cells is closely related to the occurrence and development of the diseases. Previous studies have mostly been limited to single diseases or single cell types, lacking systematic comparisons of immune profiles across multiple diseases and interactions between cell types, which has restricted our understanding of the overall pattern of immune dysregulation in rheumatic diseases. Methods: To provide a systematic characterization of the similarities and differences in immune cells among various rheumatic diseases, this study integrated single-cell transcriptome data from peripheral blood mononuclear cells of five rheumatic diseases and healthy controls. Results: Different rheumatic diseases share some immune dysregulation modules, such as impaired function of γδ T cells. We found that the functions of γδ T cells, including immune regulation and cell proliferation, were significantly decreased in five rheumatic diseases. The analysis of cell communication suggested that the MIF and GALECTIN signaling pathways play a key role in the interaction between T cells and myeloid cells in five rheumatic diseases. However, rheumatic diseases retain their specific disease characteristics, such as different myeloid activation states. Among them, the myeloid cells in Behçet's disease patients were generally found characterized by enhanced cytotoxicity, while they showed active inflammatory states in systemic lupus erythematosus. Discussion: This study systematically characterized the immune cell characteristics and interaction networks across rheumatic diseases, revealing shared and specific immune dysregulation patterns, and provided new insights into understanding the immune mechanisms of rheumatic diseases and developing targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.